<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AGALSIDASE BETA </span><br/>(a-gal'si-dase)<br/><span class="topboxtradename">Fabrazyme<br/></span><b>Classifications:</b> <span class="classification">enzyme</span>; <span class="classification">enzyme replacement</span><br/><b>Prototype: </b>Pancrelipase <br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>35 mg/vial injection</p>
<h1><a name="action">Actions</a></h1>
<p>Fabry disease is caused by a deficiency of alpha-galactosidase A resulting in an accumulation of glycosphinolipids in body
         tissues causing cardiomyopathy, renal failure, and CVA. Agalsidase beta provides an exogenous source of K-galactosidase A
         that catalyzes the breakdown of glycosphingolipids including GL-3.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of Fabry disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Safety and efficacy in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity reaction to agalsidase beta or mannitol; compromised cardiac function, mild to severe hypertension; renal
         impairment; pregnancy (category B), lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Fabry Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 1 mg/kg q2wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Give antipyretics prior to infusion.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Infusion:</span>  Bring Fabrazyme vials and supplied sterile water for injection to room temperature prior to reconstitution. Reconstitute
                  each 35 mg vial slowly injecting 7.2 mL of sterile water for injection down inside wall of vial. Roll and tilt vial gently
                  to mix but do not shake. Reconstituted vial contains 5.0 mg/mL of clear, colorless solution. Do not use if there is particulate
                  matter or if discolored. Further dilute in NS to a final total volume of 500 mL; prior to adding the volume of reconstituted
                  Fabrazyme required for the dose, remove an equal volume of NS from the 500 mL infusion bag.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Infusion:</span> Initial rate should not exceed 0.25 mg/min (15 mg/h; give more slowly if infusion-associated reactions occur). After tolerance
                  to infusion is established, may increase rate in increments of 0.050.08 mg/min (increments of 3 to 5 mg/h) for each
                  subsequent infusion.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> Do not infuse with other products. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store refrigerated until needed. Vials are for single use. Discard any unused portion. Do <small>NOT</small> use after expiration date.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Fever, skeletal pain, pallor, rigors, temperature change sensation,</span> ataxia, stroke. <span class="typehead">CNS:</span>
<span class="speceff-common">Dizziness, headache, paresthesia, anxiety, depression,</span> vertigo. <span class="typehead">CV:</span>
<span class="speceff-common">Chest pain, cardiomegaly, hypertension, hypotension, dependent edema,</span> bradycardia, heart failure, exacerbation of preexisting arrhythmias. <span class="typehead">GI:</span>
<span class="speceff-common">Dyspepsia, nausea, abdominal pain.</span>
<span class="typehead">Metabolic:</span>
<span class="speceff-common">Antibody development.</span>
<span class="typehead">Musculoskeletal:</span>
<span class="speceff-common">Arthrosis, skeletal pain.</span>
<span class="typehead">Respiratory:</span>
<span class="speceff-common">Bronchitis,</span> bronchospasm, laryngitis, <span class="speceff-common">pharyngitis, rhinitis,</span> sinusitis, dyspnea. <span class="typehead">Skin:</span> Pruritus, urticaria. <span class="typehead"> Special Senses:</span> Hearing loss. <span class="typehead">Urogenital:</span> Testicular pain, nephrotic syndrome. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Coadministration with <b>amiodarone, chloroquine, hydroxychloroquine, gentamicin</b> is not recommended due to potential of decreased response to agalsidase beta therapy. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Metabolism:</span> Degraded through peptide hydrolysis. <span class="typehead">Elimination:</span> Renal elimination expected to be a minor pathway. <span class="typehead">Half-Life:</span> 45102 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>During infusion, monitor for infusion-related reactions such as hypertension or hypotension, chest pain or chest tightness,
            dyspnea, fever and chills, headache, abdominal pain, pruritus and urticaria.
         </li>
<li>Slow infusion and notify physician immediately if infusion reaction occurs. Note that additional antipyretic and/or an antihistamine
            and oral steroid may reduce the symptoms.
         </li>
<li>Monitor cardiac status closely, especially with preexisting heart disease.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician if you have experienced an unusual reaction to agalsidase beta, agalsidase alfa, mannitol, other drugs, foods,
            or preservatives.
         </li>
<li>Report any of the following to physician immediately: chest pain or chest tightness, rapid heartbeat, shortness of breath
            or difficulty breathing; depression; dizziness; skin rash, hives or itching; throat tightness; swelling of the face, lips,
            neck, ears, or extremities.
         </li>
<li>Do not drive or engage in other hazardous activities until reaction to drug is known.</li>
<li>Do not breast feed without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>